Prognostic risk factors for treatment decision in pT1a,b N0M0 HER2-positive breast cancers

Antonino Musolino, Daniela Boggiani, Angelica Sikokis, Anita Rimanti, Benedetta Pellegrino, Rosa Vattiato, Paolo Sgargi, Fabio Falcini, Caterina Caminiti, Maria Michiara, Francesco Leonardi

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Although outcomes for women with breast cancers may vary by biologic subtype, patients with T1a,b N0M0 tumors have an excellent prognosis across all subgroups. HER2 overexpression occurs in 15-20% of primary breast tumors, and is associated with diminished disease-free and overall survival. The anti-HER2 monoclonal antibody trastuzumab in combination with chemotherapy is an effective treatment for all stages of HER2 positive breast cancer (bc). However, the absolute benefit decreases as the risk of recurrence lessens and no available randomized adjuvant trial has evaluated the role of trastuzumab in women with pT1a,b N0M0, HER2-positive breast tumors. These findings may explain the debate about the appropriate indication for adjuvant chemotherapy plus trastuzumab in this setting of patients. The aim of this review was to describe known and novel prognostic risk factors to be used for tailored treatment decision in pT1a,b N0M0 HER2-positive tumors. Whether patients with small HER2-positive bc may be suitable for (chemo)therapy reduction strategies, the current available data cannot exclude the need for a more aggressive treatment in a small subset of these subjects. Novel clinical prognostic factors such as interval cancer (IC) detection may help to address this clinically important controversy. A multicenter population-based cancer registry study is currently evaluating whether IC detection may identify patients with pT1a N0M0 HER2-positive tumors in whom the rate of recurrence justifies consideration for use of conventional, trastuzumab-based chemotherapy regimens.

Original languageEnglish
Pages (from-to)1-7
Number of pages7
JournalCancer Treatment Reviews
Volume43
DOIs
Publication statusPublished - 2016

Fingerprint

Breast Neoplasms
Neoplasms
Therapeutics
Recurrence
Adjuvant Chemotherapy
Combination Drug Therapy
Disease-Free Survival
Registries
Monoclonal Antibodies
Drug Therapy
Trastuzumab
Population

Keywords

  • Breast cancer
  • HER2-positive
  • Interval cancer risk
  • Prognostic factors
  • PT1a,b

ASJC Scopus subject areas

  • Oncology
  • Radiology Nuclear Medicine and imaging

Cite this

Musolino, A., Boggiani, D., Sikokis, A., Rimanti, A., Pellegrino, B., Vattiato, R., ... Leonardi, F. (2016). Prognostic risk factors for treatment decision in pT1a,b N0M0 HER2-positive breast cancers. Cancer Treatment Reviews, 43, 1-7. https://doi.org/10.1016/j.ctrv.2015.11.010

Prognostic risk factors for treatment decision in pT1a,b N0M0 HER2-positive breast cancers. / Musolino, Antonino; Boggiani, Daniela; Sikokis, Angelica; Rimanti, Anita; Pellegrino, Benedetta; Vattiato, Rosa; Sgargi, Paolo; Falcini, Fabio; Caminiti, Caterina; Michiara, Maria; Leonardi, Francesco.

In: Cancer Treatment Reviews, Vol. 43, 2016, p. 1-7.

Research output: Contribution to journalArticle

Musolino, A, Boggiani, D, Sikokis, A, Rimanti, A, Pellegrino, B, Vattiato, R, Sgargi, P, Falcini, F, Caminiti, C, Michiara, M & Leonardi, F 2016, 'Prognostic risk factors for treatment decision in pT1a,b N0M0 HER2-positive breast cancers', Cancer Treatment Reviews, vol. 43, pp. 1-7. https://doi.org/10.1016/j.ctrv.2015.11.010
Musolino, Antonino ; Boggiani, Daniela ; Sikokis, Angelica ; Rimanti, Anita ; Pellegrino, Benedetta ; Vattiato, Rosa ; Sgargi, Paolo ; Falcini, Fabio ; Caminiti, Caterina ; Michiara, Maria ; Leonardi, Francesco. / Prognostic risk factors for treatment decision in pT1a,b N0M0 HER2-positive breast cancers. In: Cancer Treatment Reviews. 2016 ; Vol. 43. pp. 1-7.
@article{ad9da14191a4491db18a2995043a6a0c,
title = "Prognostic risk factors for treatment decision in pT1a,b N0M0 HER2-positive breast cancers",
abstract = "Although outcomes for women with breast cancers may vary by biologic subtype, patients with T1a,b N0M0 tumors have an excellent prognosis across all subgroups. HER2 overexpression occurs in 15-20{\%} of primary breast tumors, and is associated with diminished disease-free and overall survival. The anti-HER2 monoclonal antibody trastuzumab in combination with chemotherapy is an effective treatment for all stages of HER2 positive breast cancer (bc). However, the absolute benefit decreases as the risk of recurrence lessens and no available randomized adjuvant trial has evaluated the role of trastuzumab in women with pT1a,b N0M0, HER2-positive breast tumors. These findings may explain the debate about the appropriate indication for adjuvant chemotherapy plus trastuzumab in this setting of patients. The aim of this review was to describe known and novel prognostic risk factors to be used for tailored treatment decision in pT1a,b N0M0 HER2-positive tumors. Whether patients with small HER2-positive bc may be suitable for (chemo)therapy reduction strategies, the current available data cannot exclude the need for a more aggressive treatment in a small subset of these subjects. Novel clinical prognostic factors such as interval cancer (IC) detection may help to address this clinically important controversy. A multicenter population-based cancer registry study is currently evaluating whether IC detection may identify patients with pT1a N0M0 HER2-positive tumors in whom the rate of recurrence justifies consideration for use of conventional, trastuzumab-based chemotherapy regimens.",
keywords = "Breast cancer, HER2-positive, Interval cancer risk, Prognostic factors, PT1a,b",
author = "Antonino Musolino and Daniela Boggiani and Angelica Sikokis and Anita Rimanti and Benedetta Pellegrino and Rosa Vattiato and Paolo Sgargi and Fabio Falcini and Caterina Caminiti and Maria Michiara and Francesco Leonardi",
year = "2016",
doi = "10.1016/j.ctrv.2015.11.010",
language = "English",
volume = "43",
pages = "1--7",
journal = "Cancer Treatment Reviews",
issn = "0305-7372",
publisher = "W.B. Saunders Ltd",

}

TY - JOUR

T1 - Prognostic risk factors for treatment decision in pT1a,b N0M0 HER2-positive breast cancers

AU - Musolino, Antonino

AU - Boggiani, Daniela

AU - Sikokis, Angelica

AU - Rimanti, Anita

AU - Pellegrino, Benedetta

AU - Vattiato, Rosa

AU - Sgargi, Paolo

AU - Falcini, Fabio

AU - Caminiti, Caterina

AU - Michiara, Maria

AU - Leonardi, Francesco

PY - 2016

Y1 - 2016

N2 - Although outcomes for women with breast cancers may vary by biologic subtype, patients with T1a,b N0M0 tumors have an excellent prognosis across all subgroups. HER2 overexpression occurs in 15-20% of primary breast tumors, and is associated with diminished disease-free and overall survival. The anti-HER2 monoclonal antibody trastuzumab in combination with chemotherapy is an effective treatment for all stages of HER2 positive breast cancer (bc). However, the absolute benefit decreases as the risk of recurrence lessens and no available randomized adjuvant trial has evaluated the role of trastuzumab in women with pT1a,b N0M0, HER2-positive breast tumors. These findings may explain the debate about the appropriate indication for adjuvant chemotherapy plus trastuzumab in this setting of patients. The aim of this review was to describe known and novel prognostic risk factors to be used for tailored treatment decision in pT1a,b N0M0 HER2-positive tumors. Whether patients with small HER2-positive bc may be suitable for (chemo)therapy reduction strategies, the current available data cannot exclude the need for a more aggressive treatment in a small subset of these subjects. Novel clinical prognostic factors such as interval cancer (IC) detection may help to address this clinically important controversy. A multicenter population-based cancer registry study is currently evaluating whether IC detection may identify patients with pT1a N0M0 HER2-positive tumors in whom the rate of recurrence justifies consideration for use of conventional, trastuzumab-based chemotherapy regimens.

AB - Although outcomes for women with breast cancers may vary by biologic subtype, patients with T1a,b N0M0 tumors have an excellent prognosis across all subgroups. HER2 overexpression occurs in 15-20% of primary breast tumors, and is associated with diminished disease-free and overall survival. The anti-HER2 monoclonal antibody trastuzumab in combination with chemotherapy is an effective treatment for all stages of HER2 positive breast cancer (bc). However, the absolute benefit decreases as the risk of recurrence lessens and no available randomized adjuvant trial has evaluated the role of trastuzumab in women with pT1a,b N0M0, HER2-positive breast tumors. These findings may explain the debate about the appropriate indication for adjuvant chemotherapy plus trastuzumab in this setting of patients. The aim of this review was to describe known and novel prognostic risk factors to be used for tailored treatment decision in pT1a,b N0M0 HER2-positive tumors. Whether patients with small HER2-positive bc may be suitable for (chemo)therapy reduction strategies, the current available data cannot exclude the need for a more aggressive treatment in a small subset of these subjects. Novel clinical prognostic factors such as interval cancer (IC) detection may help to address this clinically important controversy. A multicenter population-based cancer registry study is currently evaluating whether IC detection may identify patients with pT1a N0M0 HER2-positive tumors in whom the rate of recurrence justifies consideration for use of conventional, trastuzumab-based chemotherapy regimens.

KW - Breast cancer

KW - HER2-positive

KW - Interval cancer risk

KW - Prognostic factors

KW - PT1a,b

UR - http://www.scopus.com/inward/record.url?scp=84962033872&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84962033872&partnerID=8YFLogxK

U2 - 10.1016/j.ctrv.2015.11.010

DO - 10.1016/j.ctrv.2015.11.010

M3 - Article

C2 - 26827687

AN - SCOPUS:84962033872

VL - 43

SP - 1

EP - 7

JO - Cancer Treatment Reviews

JF - Cancer Treatment Reviews

SN - 0305-7372

ER -